By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



Company News
Orexigen (OREX) Appoints New Member Of Board Of Directors And Announces Senior Management Changes 5/23/2016 6:42:09 AM
Orexigen (OREX) Reports Business And Financial Results For The First Quarter Ended March 31, 2016 5/5/2016 6:50:45 AM
Orexigen (OREX) To Speak At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/4/2016 8:02:28 AM
Orexigen (OREX) Expands Commercial Leadership Team With Appointment Of Healthcare Industry Veteran Brian Longstreet As Senior Vice President Of Global Market Access And Development 5/3/2016 6:53:32 AM
Orexigen (OREX) Announces South Korean Approval Of Contrave (Naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients 5/2/2016 6:47:37 AM
Orexigen (OREX) Announces Upcoming Presentations At XIII International Congress On Obesity Hosted By The World Obesity Federation 4/28/2016 8:53:21 AM
Orexigen (OREX) Expands Commercial Capabilities With Appointment Of Beth Eastland, Vice President Of Sales, And Eight Additional New Employees 4/25/2016 7:42:19 AM
Orexigen (OREX) To Provide Business Update And Discuss First Quarter 2016 Financial Results On May 4, 2016 4/21/2016 6:47:45 AM
Orexigen (OREX) To Host Conference Call At 8:30 A.M. Eastern Time Today To Discuss Acquisition Of U.S. Rights To Contrave (naltrexone HCl / bupropion HCl extended release) And Central And Eastern Europe Distribution Agreement With Valeant (VRX) 3/15/2016 8:55:52 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Valeant (VRX) For Mysimba (naltrexone HCl / bupropion HCl prolonged release) For 18 Central And Eastern European Countries And Turkey 3/15/2016 6:06:48 AM